Brief: Aelis Farma FY Operating Result Turns To Loss Of EUR 8.5 Million

Aelis Farma SA

03/04/2023 16:59

April 3 (Reuters) - Aelis Farma SA  AELIS.PA :
    * CONFIRMS ITS 2023 OUTLOOK
    * AELIS FARMA REPORTS ITS 2022 ANNUAL FINANCIAL RESULTS AND
CONFIRMS ITS 2023 OUTLOOK
    * STRONG CASH POSITION OF EUR 34.4 MILLION AT DECEMBER 31,
2022
    * FY REVENUE FROM ORDINARY ACTIVITIES EUR 8.4 MILLION
    * FOR AEF0217 TO TREAT VARIOUS COGNITIVE DEFICITS, INCLUDING
THOSE
OF DOWN SYNDROME: IN 2023, MAIN OBJECTIVE WILL BE TO
SUCCESSFULLY COMPLETE PHASE 1/2 STUDY
    * THE FIRM THUS GENERATED A NET LOSS OF -€14,288 THOUSAND IN
2022,
COMPARED TO A PROFIT OF €574 THOUSAND IN 2021
    * AT DECEMBER 31, 2022, ANNUAL OPERATING LOSS WAS THUS -EUR
8,525
THOUSAND, COMPARED TO AN OPERATING PROFIT OF EUR 2,552 THOUSAND
AT DECEMBER 31, 2021
    * AEF0117 TO ADDRESS ADVERSE EFFECTS OF EXCESSIVE CANNABIS
USE:
PHASE 2B CLINICAL TRIAL ARE EXPECTED MID-2023
    * IN YEAR ENDED DECEMBER 31, 2022, COMPANY RECORDED INCOME
FROM
ORDINARY ACTIVITIES OF EUR 8.4 MILLION

Source text for Eikon:  ID:nBw5vwLxVa 
Further company coverage:  AELIS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))